Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who May Qualify: - 18 years of age - Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy 1. Phase 1b Dose Escalation: solid tumors, previously treated 2. Phase 1b Dose Expansion and Phase 2: i. NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors ii. Solid tumors, previously treated, naïve to KRAS G12C (OFF) inhibitors. - You should be able to carry out daily activities with 0 level of ability (ECOG 0) or 1 - your organs (liver, kidneys, etc.) are working well enough based on blood tests Who Should NOT Join This Trial: - Primary central nervous system (CNS) tumors - Active brain metastases - Known impairment of GI function that would alter the absorption - Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment Always talk to your doctor about whether this trial is right for you.